Lewis H. Titterton, Jr. Buys 10,000 Shares of Anixa Biosciences Inc (NASDAQ:ANIX) Stock

Key Points

• Director Transaction: Anixa Biosciences' Director Lewis H. Titterton, Jr. purchased 10,000 shares at an average price of $3.08, totaling $30,800, which increased his stake by 1.06% to 953,334 shares.
• Recent Performance: The stock recently traded at $3.06, reflecting a 12-month low of $2.07 and a high of $4.20, with a market capitalization of approximately $98.57 million.
• Analyst Ratings: Anixa Biosciences holds a consensus "Buy" rating among analysts, with a target price averaging $9.00, reflecting positive sentiment despite the company reporting a quarterly loss per share.

Anixa Biosciences Inc (NASDAQ:ANIX - Get Free Report) Director Lewis H. Titterton, Jr. acquired 10,000 shares of the business's stock in a transaction dated Thursday, July 31st. The stock was purchased at an average cost of $3.08 per share, for a total transaction of $30,800.00. Following the completion of the acquisition, the director directly owned 953,334 shares of the company's stock, valued at approximately $2,936,268.72. This trade represents a 1.06% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link.

Anixa Biosciences Stock Performance

Shares of NASDAQ:ANIX traded down $0.07 during trading on Wednesday, reaching $3.09. The stock had a trading volume of 21,793 shares, compared to its average volume of 108,232. The business has a fifty day moving average price of $3.22 and a 200-day moving average price of $2.96. The stock has a market cap of $99.37 million, a PE ratio of -8.12 and a beta of 0.43. Anixa Biosciences Inc has a 1-year low of $2.07 and a 1-year high of $4.20.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last issued its quarterly earnings results on Tuesday, June 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. Sell-side analysts expect that Anixa Biosciences Inc will post -0.41 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Wall Street Zen raised Anixa Biosciences from a "sell" rating to a "hold" rating in a report on Friday, June 6th. D. Boral Capital reissued a "buy" rating and issued a $10.00 price target on shares of Anixa Biosciences in a report on Tuesday. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $9.00.

Institutional Trading of Anixa Biosciences

Institutional investors have recently made changes to their positions in the company. Focus Partners Wealth acquired a new position in Anixa Biosciences during the fourth quarter worth $162,000. LPL Financial LLC raised its position in Anixa Biosciences by 37.2% in the fourth quarter. LPL Financial LLC now owns 42,937 shares of the company's stock valued at $100,000 after purchasing an additional 11,633 shares during the period. Jane Street Group LLC purchased a new stake in Anixa Biosciences in the fourth quarter valued at $67,000. Renaissance Technologies LLC raised its position in Anixa Biosciences by 36.5% in the fourth quarter. Renaissance Technologies LLC now owns 14,573 shares of the company's stock valued at $34,000 after purchasing an additional 3,900 shares during the period. Finally, Private Advisor Group LLC purchased a new stake in shares of Anixa Biosciences in the 1st quarter valued at $35,000. 29.13% of the stock is owned by institutional investors and hedge funds.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.